Sinensis Life Sciences Acquires Spinnovation

Sinensis Life Sciences Acquires Spinnovation

 

NEWS RELEASE | September 19, 2014, Leiden, Oss, the Netherlands (in English)

Sinensis Life Sciences Acquires Spinnovation

Sinensis Life Sciences B.V., Leiden, the Netherlands (“Sinensis”), announces today that it has acquired Spinnovation Holding B.V., Oss, the Netherlands (“Spinnovation”), a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market. Financial terms of the transaction were not disclosed.

 

The addition of Spinnovation expands and strengthens Sinensis’ chemical R&D group as in addition to NMR Spinnovation offers mass spectrometry (MS) and inductively coupled plasma (ICP) spectroscopy analyses to its customers. 

Dr Ruud Santing, CEO of Sinensis, commented: “We are excited to add Spinnovation’s analytical equipment and many years of expertise to our existing portfolio of capillary electrophoresis (CE), UPLC-QToF-MS and UPLC-TQ-MS, all techniques that are becoming more and more important in working on therapeutic proteins, monoclonal antibodies and other biologicals. Moreover, we are pleased that through Spinnovation we get a footprint in the Pivot Park in Oss housing an increasing number of (bio)pharmaceutical companies requiring GMP analytical services.”

Dr Frederic Girard, CEO of Spinnovation, commented: “The strategic fit between Spinnovation and the Sinensis group of contract laboratories is excellent, a group with many years of experience in servicing the (bio)pharmaceutical market. We are confident that with the help of Sinensis we will get a GMP license from the Dutch Healthcare Inspectorate rather soon. This license and being a part of Sinensis also means that we can further anchor our commitment to deliver turn-key solutions to our clients from drug and process development to API and product release, and accelerate our growth and realise our ambitions faster.

Spinnovation will continue to operate independently and Dr Girard will continue to lead it, reporting to Dr Santing.

 

For more information on the transaction, please contact:

Dr Marcel Langoor, Chief Business Officer of Sinensis, via telephone number +31-71-5244080 or via email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


About Sinensis Life Sciences

Sinensis Life Sciences is an independent provider of laboratory testing and manufacturing services to the international life sciences market. Sinensis’ services range from physical, chemical and microbiological quality control testing of pharmaceutical raw materials to finished dosage forms, thereby covering release, stability and validation. Its R&D departments can develop test methods from scratch or based on client methods.

In addition to testing, Sinensis has multiple aseptic manufacturing units in which small-scale compounding and fill and finish activities of clinical trial medication are performed. Labelling, packaging, storing and distributing are also covered. In-process and release testing as well as releasing the batch by a qualified person are included in this service.

Sinensis’ flexibility, reliability and ability to deliver a high comfort feeling have attracted customers from biotech start-ups to multinational generics manufacturers to big innovative pharma players. With over 140 employees and tens of years of experience Sinensis is very well capable of resolving your analytical and manufacturing challenges.

More information can be found on www.sinensislifesciences.com.

About Spinnovation

Spinnovation consists of Spinnovation Analytical and Spinnovation Biologics. The former is specialised in performing contract research and supplying contract analysis services to support the Life Science industries while the latter focuses on providing services for profiling and characterising bioprocesses, biologics and biosimilars. One specific technology developed by Spinnovation Biologics is Spedia-NMRTM, i.e. spent media analyses which gives customers detailed insight in concentration profiles of their cell culture media enabling them to optimise their cell lines and bioprocesses in a very cost efficient manner.

More information can be found on www.spinnovation-analytical.com and www.spinnovation-biological.com.

 

END.

 

 

Press Release in PDF format

  SPI-JOB-067.pdf

 

 
 

Spinnovation Analytical is part of Sinensis Life Sciences

visit website x